Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 11.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,076,600 shares of the company’s stock after purchasing an additional 207,533 shares during the quarter. Envestnet Asset Management Inc. owned about 0.18% of Teva Pharmaceutical Industries worth $33,745,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Thoroughbred Financial Services LLC raised its position in shares of Teva Pharmaceutical Industries by 14.3% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 17,592 shares of the company’s stock worth $285,000 after buying an additional 2,200 shares during the period. Dai ichi Life Insurance Company Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 5.5% in the 2nd quarter. Dai ichi Life Insurance Company Ltd now owns 52,146 shares of the company’s stock worth $847,000 after purchasing an additional 2,697 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in shares of Teva Pharmaceutical Industries by 8.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 78,319 shares of the company’s stock valued at $1,263,000 after purchasing an additional 6,192 shares in the last quarter. Cornercap Investment Counsel Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $1,048,000. Finally, Achmea Investment Management B.V. increased its position in Teva Pharmaceutical Industries by 4.6% during the 2nd quarter. Achmea Investment Management B.V. now owns 587,188 shares of the company’s stock worth $9,542,000 after purchasing an additional 26,051 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the transaction, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Jefferies Financial Group increased their price target on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Bank of America increased their target price on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Finally, Barclays boosted their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus target price of $18.89.

Teva Pharmaceutical Industries Trading Down 1.4 %

Shares of TEVA opened at $17.51 on Friday. Teva Pharmaceutical Industries Limited has a one year low of $8.06 and a one year high of $19.08. The stock has a 50-day moving average price of $17.66 and a 200 day moving average price of $16.07. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The company has a market capitalization of $19.83 billion, a P/E ratio of -42.70, a P/E/G ratio of 1.26 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The business had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.